News and Trends 21 Jul 2022 Almirall launches new call to find innovative therapies for skin diseases A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […] July 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2022 Financing round of $21M completed for drug to treat autoimmune diseases The first-round of financing to the tune of $21 million (€20.6 million), for a drug to treat autoimmune disease, has been completed between Precision Autoimmune Therapeutics (PAT) and CASI Pharmaceuticals. PAT will pay CASI a $5 million (€4.9 million) equivalent as the first instalment of the upfront payment of the sub-license agreement. In May this […] July 11, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Funding doubled for company working on breakthrough auto-immune disease therapeutics A Paris-based biotech company developing products for auto-immune diseases, announced today (June 30) that it has almost doubled its initial funding from two companies. The initial funding for Ermium Therapeutics of €6.3 million ($6.57 million) now stands at €12.3 million ($12.83 million) and has been supplied by Kurma Partners and Fountain Healthcare Partners. Ermium discovers […] June 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Deal to advance treatment for autoimmune disease worth $97M MiroBio, which is developing checkpoint agonists to treat autoimmune disease, has announced the completion of a $97 million deal. The financing is being led by Medicxi with investments from OrbiMed and Monograph Capital and existing investors Oxford Science Enterprises, Samsara Biocapital, SR One and Advent Life Sciences. Funds will primarily be used to advance MiroBio’s […] June 29, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2022 ImmunOs Therapeutics raises $74M ImmunOs Therapeutics AG, a biopharmaceutical company developing therapeutics for the treatment of cancer and autoimmune diseases, has announced the closing of an oversubscribed Series B financing round totaling $74M. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by other new investors Mission BioCapital, GL Capital, PEAK6 Strategic […] June 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2021 Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening up its developer argenx to billion-dollar revenues. Efgartigimod, to be marketed as Vyvgart, is an antibody fragment drug for use in adults with generalized myasthenia gravis. The FDA’s decision represents the first successful drug approval […] December 21, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2021 Targeted Drugs for Rare Autoimmune Disease Hit Regulatory Milestones New, more targeted treatments are on the horizon for the rare autoimmune disease ANCA-associated vasculitis, with a nod towards European approval for a first-in-class drug and positive phase II results from a rival treatment. In November, the Swiss firm Vifor Fresenius Medical Care Renal Pharma (VFMCRP) received a thumbs-up from the EMA for avacopan, a […] December 1, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2020 Record Series A for Italian Biotech Funds Autoimmune Therapy Italian biotech Enthera raised €28M in Series A funding to develop its drug candidate for type 1 diabetes and inflammatory bowel disease and take it to human trials. Enthera was founded in 2016 and is the first company to ‘graduate’ from the BiovelocITA accelerator program in Milan, which is supported by French life science investor […] July 28, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 3 Mar 2020 How Immunotherapy Could Stop and Prevent Type 1 Diabetes People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […] March 3, 2020 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2020 FDA Greenlights First Treatment for Rare Autoimmune Eye Disease An antibody drug developed by the Irish biopharma Horizon Therapeutics has been approved by the FDA for the treatment of adults with the rare autoimmune condition thyroid eye disease. The approval of the drug came ahead of schedule, with the decision originally expected in March. The drug, a monoclonal antibody, is branded as Tepezza. Thyroid […] January 22, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2019 €48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune cells called a gamma delta T-cell. ImCheck Therapeutics’ Series B round was led by Pfizer Ventures — the venture capital arm of the big pharma […] December 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2019 Argenx Raises Whopping €502M in Global Offering The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M) in a global offering on the Nasdaq Stock Exchange and Euronext Brussels. Argenx’s global offering was launched last week. It consists of a private placement in Europe as well as a public offering in the […] November 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email